Clinical trial

Evaluation de l'Impact d'un Mode de supplémentation en Vitamine D (Dose séquentielle vs Dose Quotidienne) Sur l'Incidence de l'Hypercalciurie Chez Des Sujets Des départements du Gard et de l'Hérault agés de 2 à 18 Ans. Etude contrôlée randomisée en 2 Groupes parallèles

Name
RECHMPL15_0500
Description
Recommendations for vitamin D supplementation for subjets between 2 and 18 years offer strong sequential doses of vitamin D: 2 times 100 000 units in spaced winter period of 3 months. Data from the literature show a further increase in the incidence of oxalo-calcium stones in children and adolescents associated with hypercalciuria with training Randall plates, essential step lithogenesis calcium oxalate. Knowing the links between vitamin D and urinary calcium excretion, these data lead to the question of increased sensitivity in some children with vitamin D, sensitivity could explain these situations with hypercalciuria increase the gallstone risk. This increased sensitivity to vitamin D may unmask particularly if inputs of high doses of vitamin responsible then a transient hypercalciuria with development of microcrystals.
Trial arms
Trial start
2017-12-14
Estimated PCD
2024-05-01
Trial end
2024-12-01
Status
Recruiting
Treatment
Cholecalciferol sequential dose
sequential dose administration of the treatment
Arms:
Cholecalciferol sequential dose
Other names:
Vitamin D
Cholecalciferol daily dose
daily dose administration of the treatment
Arms:
Cholecalciferol daily dose
Other names:
Vitamin D
Size
280
Primary endpoint
Changes from calcium level in urines at day 7, day 14 and day 28
day 7, day 14 and day 28
Eligibility criteria
Inclusion Criteria: * Children aged 2 to 17 years included * Obtaining informed consent of the parents signed * Participants aged 18 years included
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 280, 'type': 'ESTIMATED'}}
Updated at
2023-04-10

1 organization

1 product

1 indication